-
White-Coat HTN
Make Diabetics Walk
Treatment of Complicated Grief
-
By Norman R. Relkin, MD, PhD
Associate Professor of Clinical Neurology and Neuroscience at New York Presbyterian Hospital-Cornell Campus.
Dr. Relkin is on the speaker's bureau of Pfizer, Eisai, and Athena Diagnostics and does research for Pfizer and Merck.
-
Rifamixin, a nonabsorbed oral antibiotic, is effective for preventing traveler's diarrhea, according to new research.
-
-
By William T. Elliott, MD, FACP, and James Chan, PharmD, PhD
Dr. Elliott is Chair, Formulary Committee, Northern California Kaiser Permanente; Associate Clinical Professor of Medicine, University of California, San Francisco; Dr. Chan is Pharmacy Quality and Outcomes Manager, Kaiser Permanente, Oakland, CA. Drs. Chan and Elliott report no financial relationships to this field of study.
A synthetic analog of human amylin has been approved for the treatment of type 1 and type 2 diabetics.
Pramlintide is a 37-amino acid peptide which differs from human amylin with substitution of three amino acids at positions 25, 28, and 29. It represents the first of a new class of amylinomimetic antidiabetic compounds. It is marketed by Amylin Pharmaceuticals, Inc as Symlin.
-
-
Surveillance indicates that community-associated MRSA (CA-MRSA) strains are beginning to appear with increasing frequency in certain parts of Europe.
-
Health care-associated transmission of influenza has been documented in many different patient populations and clinical settings.
-
Soldiers who served in Iraq and Afghanistan have acquired a drug-resistant bacteria that is fueling nosocomial outbreaks in military hospitals, an epidemiologist recently reported in San Francisco at the annual meeting of the Infectious Diseases Society of America.
-
Initially sensationalized as a mystery bug, the pathogen that caused a recent outbreak that claimed 17 lives in an Toronto nursing home turned out to be one of the usual suspects: Legionella pneumophila.